Plasma Rich In Growth Factor Vs Mitomycin C In Photorefractive Keratectomy

Fernandez Vega University Institute - Eye Surface Unit  ( IUFV) Oviedo-Spain

This retrospective study included patients of the consultation of IUFV (Fernández-Vega University Institute) Corneal Unit between 2013 and 2016 who underwent PRK surgery.
They have spherical correction range from -0.25 to -8.00 D, cylinder correction range from -0.25 to -3.00 and refraction stability at least 1 year.

The mitomycin C was used in 0.02% concentration, 10 seconds per Diopter treated with maximum of 40 seconds and PRGF follow the Endoret System protocol, having contact with the surface for a minute in all cases.

Primary endpoint was evaluate and compare the efficacy and safety on both treatments, The adverse events also were reported.  

Sixty-nine patients of 117 eyes were included in the present study. Forty-four patients (72 eyes) were treated with MMC and twenty-five patients (45 eyes) with PRGF. There were no statistically significant difference in previous CDVA, sphere, cylinder or EE between the groups.

The average corneal  ablation was 29.3 ± 12.6 µm, and the remanent stroma was 491.4 ± 44.5 µm. The epithelization time was 63.7 ± 12.3 hours there was not statistically significant difference between the treatments.

The corneal endothelial cell density in both groups was very similar (p = 0.054), there was no was statistically significant difference between treatments in efficacy (p = 0.062) and security (p = 0.158)

There was no reports of  adverse effects in this study

The use of PRGF in prevention of corneal opacity is  as effective and safe as Mitomicin C, with no recurrence or corneal haze in one year of follow up